Cullinan Therapeutics Inc [CGEM] stock is trading at $12.02, down -6.82%. An important factor to consider is whether the stock is rising or falling in short-term value. The CGEM shares have gain 9.77% over the last week, with a monthly amount drifted -5.87%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Cullinan Therapeutics Inc [NASDAQ: CGEM] stock has seen the most recent analyst activity on October 24, 2024, when UBS initiated its Buy rating and assigned the stock a price target of $30. Previously, Stifel started tracking the stock with Buy rating on May 01, 2024, and set its price target to $40. On April 15, 2024, William Blair initiated with a Outperform rating. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $30 on February 15, 2024. TD Cowen initiated its recommendation with a Outperform. BTIG Research started tracking with a Buy rating for this stock on November 21, 2022, and assigned it a price target of $20. In a note dated April 27, 2021, Morgan Stanley upgraded an Overweight rating on this stock but restated the target price of $40.
Cullinan Therapeutics Inc [CGEM] stock has fluctuated between $9.55 and $30.19 over the past year. Currently, Wall Street analysts expect the stock to reach $34 within the next 12 months. Cullinan Therapeutics Inc [NASDAQ: CGEM] shares were valued at $12.02 at the most recent close of the market. An investor can expect a potential return of 182.86% based on the average CGEM price forecast.
Analyzing the CGEM fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -0.27 and Total Capital is -0.3.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.59 points at the first support level, and at 11.17 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.66, and for the 2nd resistance point, it is at 13.31.
Ratios To Look Out For
For context, Cullinan Therapeutics Inc’s Current Ratio is 24.46. On the other hand, the Quick Ratio is 24.46, and the Cash Ratio is 4.22.
Transactions by insiders
Recent insider trading involved AHMED NADIM, President and CEO, that happened on Dec 24 ’24 when 8400.0 shares were sold. Chief Scientific Officer, Michaelson Jennifer completed a deal on Dec 18 ’24 to sell 4693.0 shares. Meanwhile, Chief Medical Officer Jones Jeffrey Alan sold 4632.0 shares on Dec 18 ’24.
